In IBS-C clinical trials, diarrhea occurred in 20% of patients vs 3% on placebo.

FORBES: FDA Approves New Drug For Irritable Bowel Disorder (Update)

The FDA has announced that it has approved a new drug to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults.

FORBES: FDA Approves New Drug For Irritable Bowel Disorder (Update)

In the FDA press release, the FDA states that according to the National Institutes of Health, an estimated 15.3 million people are affected by IBS, and IBS-C is a subtype characterized mainly by abdominal pain and by hard or lumpy stools at least 25 percent of the time and loose or watery stools less than 25 percent of the time.

FORBES: FDA Approves New Drug For Irritable Bowel Disorder (Update)